Zobrazeno 1 - 10
of 193
pro vyhledávání: ''
Autor:
Lyndsey S. Crump, Traci R. Lyons, Elena Shagisultanova, Peter Kabos, Virginia F. Borges, Aryana R Rasti, Michelle Borakove, Benjamin A Harrison, Jessica K. Hall
Publikováno v:
Mol Cancer Ther
Breast cancers that express hormonal receptors (HR) and HER2 display resistance to targeted therapy. Tumor-promotional signaling from the HER2 and estrogen receptor (ER) pathways converges at the cyclin D1 and cyclin-dependent kinases (CDK) 4 and 6 c
Autor:
Daniel L. Flynn, Jarnail Singh, Bryan D. Smith, César Serrano, Alfonso García-Valverde, Anu Gupta
Publikováno v:
Molecular Cancer Therapeutics. 20:1234-1245
The majority of gastrointestinal stromal tumors (GIST) harbor constitutively activating mutations in KIT tyrosine kinase. Imatinib, sunitinib, and regorafenib are available as first-, second-, and third-line targeted therapies, respectively, for meta
Autor:
Takahiro Kodama, Yuta Myojin, Daisuke Motooka, Yu Sato, Ayumu Taguchi, Ryotaro Sakamori, Kazuki Maesaka, Satoshi Tanaka, Tetsuo Takehara, Kazuyoshi Ohkawa, Hayato Hikita, Tomohide Tatsumi, Yoshito Hayashi, Hidetoshi Eguchi, Yuichi Abe, Eiji Mita
Publikováno v:
Clinical Cancer Research. 27:1150-1161
Purpose: Hepatocellular carcinoma (HCC) is characterized by high intertumor heterogeneity of genetic drivers. Two multitarget tyrosine kinase inhibitors (TKI), lenvatinib and sorafenib, are used as standard-of-care chemotherapeutics in patients with
Autor:
Xixi Cao, Jamunarani Veeraraghavan, Shunqiang Li, Martin Shea, Lanfang Qin, Ying Tan, Susan G. Hilsenbeck, Xian Wang, Xiaosong Wang, Yiheng Hu, Jin-Ah Kim, Ling Lin, Tamika Mitchell, Rachel Schiff, Chia Chia Liu, Suet Kee Loo, Matthew J. Ellis, Sanghoon Lee
Publikováno v:
Clin Cancer Res
Purpose: Endocrine resistance remains a major clinical challenge in estrogen receptor (ER)–positive breast cancer. Despite the encouraging results from clinical trials for the drugs targeting known survival signaling, relapse is still inevitable. T
Autor:
Salvatore Siena, Daniel Moya-Rull, Andrea Sartore-Bianchi, Emanuele Rausa, Annalisa Petrelli, Annunziata Gloghini, Brian M. Alexander, Daniela Conticelli, Asa Dahle-Smith, Sara Erika Bellomo, Filippo Pietrantonio, J. Lee, Siraj M. Ali, Giovanni Sgroi, Vincent A. Miller, Federica Morano, Salvatore Corallo, Uberto Fumagalli, Silvia Giordano, Maria Di Bartolomeo, Caterina Marchiò, Giovanni de Manzoni, Anna Sapino, Antonino Sottile, Stefano De Pascale, Gian Luca Baiocchi, Laura D'Errico, Silvia Marsoni, Rossella Reddavid, Simona Corso, Michele Prisciandaro, Stefania Durando, Zosia Miedzybrodzka, Cristina Migliore, Alexa B. Schrock, Russell D. Petty, Maria Apicella, Jeffrey S. Ross, Maurizio Degiuli, Sarah Molfino, Maria Bencivenga, Stefano Ughetto
Publikováno v:
Clinical Cancer Research. 27:3126-3140
Purpose: Gastric and gastroesophageal adenocarcinomas represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of patients with advanced gastroesophageal adenocarcinoma is poor. Randomi
Autor:
Aaron Smith, Peter Johnström, Katarina Varnäs, James Atkinson, Minghui Zhao, Nicole Strittmatter, Yumei Yan, Ryosuke Arakawa, Nicola Colclough, Annika Janefeldt, M. Raymond V. Finlay, Albert D. Windhorst, Evgeny Revunov, Natasha A. Karp, Kan Chen, Lin Zhang, Gareth Maglennon, Peter Barton, Richard J. A. Goodwin, Ana Vazquez-Romero, Magnus Schou, Akihiro Takano, Gail L. Wrigley, Darren Cross, Mikhail Kondrashov, Mohammad Mahdi Moein, Zack Cheng, Paul D. Smith, Sally J. Adua, Richard A. Ward, Lars Farde, James W.T. Yates, Joanne Wilson, Jonas Malmquist, Don X. Nguyen
Publikováno v:
Colclough, N, Chen, K, Johnstrom, P, Strittmatter, N, Yan, Y, Wrigley, G L, Schou, M, Goodwin, R, Varnas, K, Adua, S J, Zhao, M, Nguyen, D X, Maglennon, G, Barton, P, Atkinson, J, Zhang, L, Janefeldt, A, Wilson, J, Smith, A, Takano, A, Arakawa, R, Kondrashov, M, Malmquist, J, Revunov, E, Vazquez-Romero, A, Moein, M M, Windhorst, A D, Karp, N A, Finlay, R V, Ward, R A, Yates, J W T, Smith, P D, Farde, L, Cheng, Z & Cross, D A E 2021, ' Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs ', Clinical Cancer Research, vol. 27, no. 1, pp. 189-201 . https://doi.org/10.1158/1078-0432.CCR-19-1871
Clinical Cancer Research, 27(1), 189-201. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(1), 189-201. American Association for Cancer Research Inc.
Purpose: Osimertinib is a potent and selective EGFR tyrosine kinase inhibitor (EGFR-TKI) of both sensitizing and T790M resistance mutations. To treat metastatic brain disease, blood–brain barrier (BBB) permeability is considered desirable for incre
Autor:
Peter S. Hammerman, Jing Yuan, Lesley A. Mathews Griner, Peter Aspesi, Daniel J. McKay, Gwynn Pardee, Hui Qin Wang, Kelli-Ann Monaco, Ribo Guo, Kenneth Crawford, Stephania Widger, Darrin Stuart, Vesselina G. Cooke, Karen Bui, Felipa A. Mapa, Yuji Mishina, Mariela Jaskelioff, Jeffrey A. Engelman, Paul Fordjour, Emma Labrot, Giordano Caponigro, Stacy Higgins, Jessi Ambrose, John Fuller, Jinsheng Liang, John Green, Scott Delach
Publikováno v:
Clinical Cancer Research. 27:2061-2073
Purpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254. Experimental Design: LXH254 was profiled in biochemical, in vitro, and in vivo assay
Publikováno v:
Clin Cancer Res
Liver cancer is the fourth leading cause of cancer-related mortality worldwide and incidence is on the rise. Hepatocellular carcinoma (HCC) is the most common form of liver cancer, with a complex etiology and limited treatment options. The standard-o
Autor:
Z Yang, Arlene Chan, Pierfranco Conte, Sara M. Tolaney, Thomas Bachelot, Yanyun Chen, Nan Lin, Véronique Diéras, Peter Kabos, Ahmad Awada, Carey K. Anders, Melissa M. Bear, Solmaz Sahebjam, Denise A. Yardley, Emilie Le Rhun, Sonya C. Chapman
Publikováno v:
Clinical Cancer Research. 26:5310-5319
Purpose:The primary objective was to evaluate intracranial objective response rate (iORR) in patients receiving abemaciclib with brain or leptomeningeal metastases (LM) secondary to hormone receptor–positive (HR+) metastatic breast cancer (MBC). Se
Autor:
Chi Luo, Elizabeth A. Perry, Kfir Sharabi, Pere Puigserver, Lipika Goyal, Andrew X. Zhu, Maximilian Hatting, Jiaxin Liang, Clint D.J. Tavares, Piotr Sicinski, Amitabh Srivastava, Marc Bilodeau
Publikováno v:
Cancer Res
Type 2 diabetes, which is mainly linked to obesity, is associated with increased incidence of liver cancer. We have previously found that in various models of obesity/diabetes, hyperinsulinemia maintains heightened hepatic expression of cyclin D1, su